Skip to main content

Table 3 Adverse events through week 52 and week 112 for patients who received at least one administration of golimumab

From: Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age

 

Patients

< 65 years

Patients ≥ 65 years

Patients < 70 years

Patients ≥ 70 years

Patients < 75 years

Patients ≥ 75 years

Patients, n

508

76

547

37

574

10

Through week 52

 Mean duration of follow-up, weeks

43.5

43.2

43.6

41.8

43.5

40.5

 Mean number of golimumab infusions

5.9

5.8

5.9

5.6

5.9

5.4

 Patients with ≥ 1 AE

355 (69.9)

52 (68.4)

379 (69.3)

28 (75.7)

397 (69.2)

10 (100.0)

 Patients with infections

214 (42.1)

30 (39.5)

227 (41.5)

17 (45.9)

239 (41.6)

5 (50.0)

 Patients with ≥ 1 SAE

45 (8.9)

9 (11.8)

49 (9.0)

5 (13.5)

50 (8.7)

4 (40.0)

 Patients with serious infections

7 (1.4)

4 (5.3)

10 (1.8)

1 (2.7)

10 (1.7)

1 (10.0)

Through week 112

 Mean duration of follow-up, weeks

96.6

90.9

96.4

88.7

96.2

76.9

 Mean number of golimumab infusions

12.0

11.3

12.0

10.9

12.0

9.4

 Patients with ≥ 1 AE

417 (82.1)

61 (80.3)

445 (81.4)

33 (89.2)

468 (81.5)

10 (100.0)

 Patients with infections

262 (51.6)

42 (55.3)

279 (51.0)

25 (67.6)

297 (51.7)

7 (70.0)

 Patients with ≥ 1 SAE

90 (17.7)

19 (25.0)

97 (17.7)

12 (32.4)

102 (17.8)

7 (70.0)

 Patients with serious infections

27 (5.3)

9 (11.8)

32 (5.9)

4 (10.8)

34 (5.9)

2 (20.0)

  1. Data presented as n (%) unless otherwise noted
  2. AE adverse event, SAE serious adverse event